'The new drug, Cobenfy, also influences dopamine levels, but it does so indirectly, by changing levels of another neurotransmitter, acetylcholine. The new approach, researchers hope, will address some of the most intractable aspects of the disease, like lack of motivation and inability to feel pleasure'

https://www.nytimes.com/2024/09/26/health/fda-schizophrenia-drug.html